Updates are available Correction dated 2022-02-07
Click to view Correction: https://doi.org/10.1186/s13073-022-01014-0
-
Authors
Zhu, Na
Pauciulo, Michael W.
Welch, Carrie L.
Lutz, Katie A.
Coleman, Anna W.
Gonzaga-Jauregui, Claudia
Wang, Jiayao
Grimes, Joseph M.
Martin, Lisa J.
He, Hua
Hirsch, Russel
White, R. James
Simon, Marc
Badesch, David
Rosenzweig, Erika
Burger, Charles
Chakinala, Murali
Thenappan, Thenappan
Elliott, Greg
Simms, Robert
Farber, Harrison
Frantz, Robert
Elwing, Jean
Hill, Nicholas
Ivy, Dunbar
Klinger, James
Nathan, Steven
Oudiz, Ronald
Robbins, Ivan
Schilz, Robert
Fortin, Terry
Wilt, Jeffrey
Yung, Delphine
Austin, Eric
Ahmad, Ferhaan
Bhatt, Nitin
Lahm, Tim
Frost, Adaani
Safdar, Zeenat
Rehman, Zia
Walter, Robert
Torres, Fernando
Bakshi, Sahil
Archer, Stephen
Argula, Rahul
Barnett, Christopher
Benza, Raymond
Desai, Ankit
Maddipati, Veeranna
Shen, Yufeng
Chung, Wendy K.
Nichols, William C. http://orcid.org/0000-0003-1242-9237
,
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (hl105333, hl060056)
National Institute of General Medical Sciences (gm120609)
- License Information
-
More Information
Article History
Received: 3 July 2019
Accepted: 6 November 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: This study was approved by the Cincinnati Children’s Hospital Medical Center Institutional Review Board (IRB) along with the individual IRBs at each of the enrolling centers’ institutions. All patients have signed consent forms which are on file at the individual enrolling centers. No protected health information (PHI) on any patients enrolled in the PAH Biobank is forwarded to the PAH Biobank. Only the individual enrolling centers have the ability to re-contact any of the patients enrolled in the study. All research using these patient samples conformed to the principles of the Helsinski Declaration.
: Written informed consent for publication was obtained at enrollment.
: CG-J is a full-time employee of the Regeneron Genetics Center from Regeneron Pharmaceuticals Inc. and receives stock options as part of compensation. The remaining authors declare that they have no competing interests.
